ReviewInternational journal of women's health2026
Fertility-Sparing Management in Ovarian Cancer: A Systematic Review.
Review in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fertility-sparing management (FSM) has emerged as an important consideration in young women with ovarian cancer, particularly as survival outcomes improve and preservation of reproductive potential becomes a key quality-of-life priority. However, the oncologic safety and reproductive efficacy of FSM remain incompletely defined. We conducted a systematic review in accordance with PRISMA 2020 guidelines (PROSPERO ID: CRD420261368106) to evaluate oncologic and reproductive outcomes following FSM in ovarian tumors. PubMed/MEDLINE, EMBASE, Scopus, and Cochrane CENTRAL were searched for studies published between January 1995 and September 2025. Eligible studies included women undergoing FSM with reported oncologic and/or reproductive outcomes. Of 464 records identified, 56 studies involving approximately 7000 participants across multiple countries met the inclusion criteria. Included populations encompassed borderline ovarian tumors (BOT), epithelial ovarian cancer (EOC), malignant ovarian germ cell tumors (MOGCT), and sex cord-stromal tumors (SCST), predominantly at early-stage disease. Recurrence rates ranged from 5% to 76% in BOT, 5% to 20% in early-stage EOC, and were generally below 10% in MOGCT and SCST. Five-year disease-free survival ranged from 80% to 95% in BOT and early-stage EOC and exceeded 85-95% in MOGCT and SCST, while overall survival exceeded 90% in BOT and 85-95% in early-stage EOC. Pregnancy rates ranged from 25% to 88%, with live birth rates between 20% and 80%. Most pregnancies occurred spontaneously, although assisted reproductive technologies improved reproductive success without increasing recurrence risk. Fertility-sparing management appears to be oncologically safe in carefully selected patients while preserving meaningful reproductive potential. Despite heterogeneity across studies, future research should focus on prospective designs with standardized outcome reporting and longer follow-up to optimize patient selection and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.